Identification of potential non-nucleoside MraY inhibitors for tuberculosis chemotherapy using structure-based virtual screening

References

• Brandish, P. E., Kimura, K. I., Inukai, M., Southgate, R., Lonsdale, J. T., & Bugg, T. D. H. (1996). Modes of action of tunicamycin, liposidomycin B, and mureidomycin A: Inhibition of phospho-N-acetylmuramyl-pentapeptide translocase from Escherichia coli. Antimicrobial Agents and Chemotherapy, 40(7), 1640–1644. https://doi.org/https://doi.org/10.1128/aac.40.7.1640
   PubMed Web of Science ®Google Scholar
• Campaniço, A., Moreira, R., & Lopes, F. (2018). Drug discovery in tuberculosis. New drug targets and antimycobacterial agents. European Journal of Medicinal Chemistry, 150, 525–545. https://doi.org/https://doi.org/10.1016/j.ejmech.2018.03.020
   PubMed Web of Science ®Google Scholar
• Cheng, F., Li, W., Zhou, Y., Shen, J., Wu, Z., Liu, G., Lee, P. W., & Tang, Y. (2012). admetSAR: A comprehensive source and free tool for assessment of chemical ADMET properties. Journal of Chemical Information and Modeling, 52(11), 3099–3105. https://doi.org/https://doi.org/10.1021/ci300367a
   PubMed Web of Science ®Google Scholar
• Chenna, R., Sugawara, H., Koike, T., Lopez, R., Gibson, T. J., Higgins, D. G., & Thompson, J. D. (2003). Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res, 31(13), 3497–3500. https://doi.org/https://doi.org/10.1093/nar/gkg500
   PubMed Web of Science ®Google Scholar
• Chung, B. C., Mashalidis, E. H., Tanino, T., Kim, M., Matsuda, A., Hong, J., Ichikawa, S., & Lee, S.-Y. (2016). Structural insights into inhibition of lipid I production in bacterial cell wall synthesis. Nature, 533(7604), 557–560. https://doi.org/https://doi.org/10.1038/nature17636
   PubMed Web of Science ®Google Scholar
• Chung, B. C., Zhao, J., Gillespie, R. A., Kwon, D.-Y., Guan, Z., Hong, J., Zhou, P., & Lee, S.-Y. (2013). Crystal structure of MraY, an essential membrane enzyme for bacterial cell wall synthesis. Science, 341(6149), 1012–1016. https://doi.org/https://doi.org/10.1126/science.1236501
   PubMed Web of Science ®Google Scholar
• Cui, Z., Wang, X., Koppermann, S., Thorson, J. S., Ducho, C., & Van Lanen, S. G. (2018). Antibacterial muraymycins from mutant strains of streptomyces sp. NRRL 30471. Journal of Natural Products, 81(4), 942–948. https://doi.org/https://doi.org/10.1021/acs.jnatprod.7b01054
   PubMed Web of Science ®Google Scholar
• Dini, C., Didier-Laurent, S., Drochon, N., Feteanu, S., Guillot, J. C., Monti, F., Uridat, E., Zhang, J., & Aszodi, J. (2002). Synthesis of sub-micromolar inhibitors of MraY by exploring the region originally occupied by the diazepanone ring in the liposidomycin structure. Bioorganic & Medicinal Chemistry Letters, 12(8), 1209–1213. https://doi.org/https://doi.org/10.1016/S0960-894X(02)00109-9
   PubMed Web of Science ®Google Scholar
• Dini, C., Drochon, N., Guillot, J. C., Mauvais, P., Walter, P., & Aszodi, J. (2001). Synthesis of analogues of the O-β-D-Ribofuranosyl nucleoside moiety of liposidomycins. Part 2: Role of the hydroxyl groups upon the inhibition of MraY. Bioorganic & Medicinal Chemistry Letters, 11(4), 533–536. https://doi.org/https://doi.org/10.1016/S0960-894X(00)00714-9
   PubMed Web of Science ®Google Scholar
• Ebejer, J.-P., Charlton, M. H., & Finn, P. W. (2016). Are the physicochemical properties of antibacterial compounds really different from other drugs? Journal of Cheminformatics, 8(1), 30 https://doi.org/https://doi.org/10.1186/s13321-016-0143-5
   PubMedGoogle Scholar
• Fer, M. J., Bouhss, A., Patrão, M., Le Corre, L., Pietrancosta, N., Amoroso, A., Joris, B., Mengin-Lecreulx, D., Calvet-Vitale, S., & Gravier-Pelletier, C. (2015). 5'-Methylene-triazole-substituted-aminoribosyl uridines as MraY inhibitors: Synthesis, biological evaluation and molecular modeling. Organic & Biomolecular Chemistry, 13(26), 7193–7222. https://doi.org/https://doi.org/10.1039/c5ob00707k
   PubMed Web of Science ®Google Scholar
• Hakulinen, J. K., Hering, J., Brändén, G., Chen, H., Snijder, A., Ek, M., & Johansson, P. (2017). MraY-antibiotic complex reveals details of tunicamycin mode of action. Nature Chemical Biology, 13(3), 265–267. https://doi.org/https://doi.org/10.1038/nchembio.2270
   PubMed Web of Science ®Google Scholar
• Hirano, S., Ichikawa, S., & Matsuda, A. (2008). Synthesis of caprazamycin analogues and their structure-activity relationship for antibacterial activity. The Journal of Organic Chemistry, 73(2), 569–577. https://doi.org/https://doi.org/10.1021/jo702264e
   PubMed Web of Science ®Google Scholar
• Hotoda, H., Daigo, M., Furukawa, M., Murayama, K., Hasegawa, C. A., Kaneko, M., Muramatsu, Y., Ishii, M. M., Miyakoshi, S-i., Takatsu, T., Inukai, M., Kakuta, M., Abe, T., Fukuoka, T., Utsui, Y., & Ohya, S. (2003). Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: Acylated derivatives of capuramycin-related compounds. Bioorganic & Medicinal Chemistry Letters, 13(17), 2833–2836. https://doi.org/https://doi.org/10.1016/S0960-894X(03)00597-3
   PubMed Web of Science ®Google Scholar
• Hotoda, H., Furukawa, M., Daigo, M., Murayama, K., Kaneko, M., Muramatsu, Y., Ishii, M. M., Miyakoshi, S-i., Takatsu, T., Inukai, M., Kakuta, M., Abe, T., Harasaki, T., Fukuoka, T., Utsui, Y., & Ohya, S. (2003). Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: Substitution of the azepan-2-one moiety of capuramycin. Bioorganic & Medicinal Chemistry Letters, 13(17), 2829–2832. https://doi.org/https://doi.org/10.1016/S0960-894X(03)00596-1
   PubMed Web of Science ®Google Scholar
• Ichikawa, S., Yamaguchi, M., Hsuan, L. S., Kato, Y., & Matsuda, A. (2015). Carbacaprazamycins: Chemically stable analogues of the caprazamycin nucleoside antibiotics. ACS Infectious Diseases, 1(4), 151–156. https://doi.org/https://doi.org/10.1021/id5000376
   PubMed Web of Science ®Google Scholar
• Igarashi, M., Nakagawa, N., Doi, N., Hattori, S., Naganawa, H., & Hamada, M. (2003). Caprazamycin B, a novel anti-tuberculosis antibiotic, from Streptomyces sp. The Journal of Antibiotics, 56(6), 580–583. https://doi.org/https://doi.org/10.7164/antibiotics.56.580
   PubMed Web of Science ®Google Scholar
• Ii, K., Ichikawa, S., Al-Dabbagh, B., Bouhss, A., & Matsuda, A. (2010). Function-oriented synthesis of simplified caprazamycins: Discovery of oxazolidine-containing uridine derivatives as antibacterial agents against drug-resistant bacteria. Journal of Medicinal Chemistry, 53(9), 3793–3813. https://doi.org/https://doi.org/10.1021/jm100243n
   PubMed Web of Science ®Google Scholar
• Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997). Development and validation of a genetic algorithm for flexible docking. Journal of Molecular Biology, 267(3), 727–748. https://doi.org/https://doi.org/10.1006/jmbi.1996.0897
   PubMed Web of Science ®Google Scholar
• Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. Journal of Chemical Physics, 79(2), 926–935. https://doi.org/https://doi.org/10.1063/1.445869
   Web of Science ®Google Scholar
• Koppermann, S., Cui, Z., Fischer, P. D., Wang, X., Ludwig, J., Thorson, J. S., Van Lanen, S. G., & Ducho, C. (2018). Insights into the target interaction of naturally occurring muraymycin nucleoside antibiotics. ChemMedChem., 13(8), 779–784. https://doi.org/https://doi.org/10.1002/cmdc.201700793
   PubMed Web of Science ®Google Scholar
• Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011). The challenge of new drug discovery for tuberculosis. Nature, 469(7331), 483–490. https://doi.org/https://doi.org/10.1038/nature09657
   PubMed Web of Science ®Google Scholar
• Lecerclé, D., Clouet, A., Al-Dabbagh, B., Crouvoisier, M., Bouhss, A., Gravier-Pelletier, C., & Le Merrer, Y. (2010). Bacterial transferase MraY inhibitors: Synthesis and biological evaluation. Bioorganic & Medicinal Chemistry, 18(12), 4560–4569. https://doi.org/https://doi.org/10.1016/j.bmc.2010.04.023
   PubMed Web of Science ®Google Scholar
• Liu, H., Patel, R. Y., & Doerksen, R. J. (2014). Structure of the cannabinoid receptor 1: Homology modeling of its inactive state and enrichment study based on CB1 antagonist docking. Med. Chem. Comm, 5(9), 1297–1302. https://doi.org/https://doi.org/10.1039/C4MD00121D
   Google Scholar
• Mallavarapu, B. D., Abdullah, M., Saxena, S., & Guruprasad, L. (2019). Inhibitor binding studies of Mycobacterium tuberculosis MraY (Rv21 56c): Insights from molecular modeling, docking, and simulation studies. Journal of Biomolecular Structure & Dynamics, 37(14), 3751–3763. https://doi.org/https://doi.org/10.1080/07391102.2018.1526715
   PubMed Web of Science ®Google Scholar
• Mashalidis, E. H., Kaeser, B., & Terasawa, Y. (2019). Chemical logic of MraY inhibition by antibacterial nucleoside natural products. Nature Communications, 10(1), 1–12. https://doi.org/https://doi.org/10.1038/s41467-019-10957-9
   PubMedGoogle Scholar
• Mihalyi, A., Jamshidi, S., Slikas, J., & Bugg, T. D. H. (2014). Identification of novel inhibitors of phospho-MurNAc-pentapeptide translocase MraY from library screening: Isoquinoline alkaloid michellamine B and xanthene dye phloxine B. Bioorganic & Medicinal Chemistry, 22(17), 4566–4571. https://doi.org/https://doi.org/10.1016/j.bmc.2014.07.035
   PubMed Web of Science ®Google Scholar
• Mitachi, K., Yun, H. G., Kurosu, S. M., Eslamimehr, S., Lemieux, M. R., Klaić, L., Clemons, W. M., & Kurosu, M. (2018). Novel FR-900493 analogues that Inhibit the outgrowth of clostridium difficile spores. ACS Omega, 3(2), 1726–1739. https://doi.org/https://doi.org/10.1021/acsomega.7b01740
   PubMed Web of Science ®Google Scholar
• Mravljak, J., Monasson, O., Al-Dabbagh, B., Crouvoisier, M., Bouhss, A., Gravier-Pelletier, C., & Le Merrer, Y. (2011). Synthesis and biological evaluation of a diazepanone-based library of liposidomycins analogs as MraY inhibitors. European Journal of Medicinal Chemistry, 46(5), 1582–1592. https://doi.org/https://doi.org/10.1016/j.ejmech.2011.02.006
   PubMed Web of Science ®Google Scholar
• Nakamura, H., Tsukano, C., Yasui, M., Yokouchi, S., Igarashi, M., & Takemoto, Y. (2015). Total synthesis of (-)-caprazamycin A. Angewandte Chemie, 54(10), 3136–3139. https://doi.org/https://doi.org/10.1002/anie.201411954
   Google Scholar
• Nakaya, T., Matsuda, A., & Ichikawa, S. (2015). Design, synthesis and biological evaluation of 5'-C-piperidinyl-5'-O-aminoribosyluridines as potential antibacterial agents. Organic & Biomolecular Chemistry, 13(28), 7720–7735. https://doi.org/https://doi.org/10.1039/c5ob01037c
   PubMed Web of Science ®Google Scholar
• Pandey, P., Avula, B., Khan, I. A., Khan, S. I., Navarro, V. J., Doerksen, R. J., & Chittiboyina, A. G. (2020). Potential modulation of human NAD[P]H-quinone oxidoreductase 1 (NQO1) by EGCG and its metabolites – A systematic computational study. Chemical Research in Toxicology, 33(11), 2749–2764. https://doi.org/https://doi.org/10.1021/acs.chemrestox.9b00450
   PubMed Web of Science ®Google Scholar
• Roos, K., Wu, C., Damm, W., Reboul, M., Stevenson, J. M., Lu, C., Dahlgren, M. K., Mondal, S., Chen, W., Wang, L., Abel, R., Friesner, R. A., & Harder, E. D. (2019). OPLS3e: Extending force field coverage for drug-like small molecules. Journal of Chemical Theory and Computation, 15(3), 1863–1874. https://doi.org/https://doi.org/10.1021/acs.jctc.8b01026
   PubMed Web of Science ®Google Scholar
• Salam, N. K., Nuti, R., & Sherman, W. (2009). Novel method for generating structure-based pharmacophores using energetic analysis. Journal of Chemical Information and Modeling, 49(10), 2356–2368. https://doi.org/https://doi.org/10.1021/ci900212v
   PubMed Web of Science ®Google Scholar
• Šali, A., & Blundell, T. L. (1993). Comparative protein modelling by satisfaction of spatial restraints. Journal of Molecular Biology, 234(3), 779–815. https://doi.org/https://doi.org/10.1006/jmbi.1993.1626
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2020-1: Canvas. (2020). Schrödinger, LLC.
   Google Scholar
• Schrödinger Release 2020-1: Epik. (2020). Schrödinger, LLC.
   Google Scholar
• Schrödinger Release 2020-1: Glide. (2020). Schrödinger, LLC.
   Google Scholar
• Schrödinger Release 2020-1: Induced Fit Docking protocol; Glide. (2020). Schrödinger, LLC., Prime, Schrödinger, LLC., 2020.
   Google Scholar
• Schrödinger Release 2020-1: Phase. (2020). Schrödinger, LLC.
   Google Scholar
• Schrödinger Release 2020-1: Prime. (2020). Schrödinger, LLC.
   Google Scholar
• Stoddard, S. V., Stoddard, S. D., Oelkers, B. K., Fitts, K., Whalum, K., Whalum, K., Hemphill, A. D., Manikonda, J., Martinez, L. M., Riley, E. G., Roof, C. M., Sarwar, N., Thomas, D. M., Ulmer, E., Wallace, F. E., Pandey, P., & Roy, S. (2020). Optimization rules for SARS-CoV-2 Mpro antivirals: Ensemble docking and exploration of the coronavirus protease active site. Viruses, 12(9), 942. https://doi.org/https://doi.org/10.3390/v12090942
   PubMed Web of Science ®Google Scholar
• Tanino, T., Al-Dabbagh, B., Mengin-Lecreulx, D., Bouhss, A., Oyama, H., Ichikawa, S., & Matsuda, A. (2011). Mechanistic analysis of muraymycin analogues: A guide to the design of MraY inhibitors. Journal of Medicinal Chemistry, 54(24), 8421–8439. https://doi.org/https://doi.org/10.1021/jm200906r
   PubMed Web of Science ®Google Scholar
• Tanino, T., Ichikawa, S., Shiro, M., & Matsuda, A. (2010). Total synthesis of (-)-muraymycin D2 and its epimer. The Journal of Organic Chemistry, 75(5), 1366–1377. https://doi.org/https://doi.org/10.1021/jo9027193
   PubMed Web of Science ®Google Scholar
• Walsh, C. T., & Zhang, W. (2011). Chemical logic and enzymatic machinery for biological assembly of peptidyl nucleoside antibiotics. ACS Chemical Biology, 6(10), 1000–1007. https://doi.org/https://doi.org/10.1021/cb200284p
   PubMed Web of Science ®Google Scholar
• Winn, M., Goss, R. J. M., Kimura, K., & Bugg, T. D. H. (2010). Antimicrobial nucleoside antibiotics targeting cell wall assembly: Recent advances in structure-function studies and nucleoside biosynthesis. Natural Product Reports, 27(2), 279–304. https://doi.org/https://doi.org/10.1039/B816215H
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2020, May 16). Global tuberculosis report 2019. https://www.who.int/news-room/fact-sheets/detail/tuberculosis.
   Google Scholar
• Yoo, J., Mashalidis, E. H., Kuk, A. C. Y., Yamamoto, K., Kaeser, B., Ichikawa, S., & Lee, S.-Y. (2018). GlcNAc-1-P-transferase-tunicamycin complex structure reveals basis for inhibition of N-glycosylation. Nature Structural & Molecular Biology, 25(3), 217–224. https://doi.org/https://doi.org/10.1038/s41594-018-0031-y
   PubMed Web of Science ®Google Scholar